doxorubicin and cisplatin
Phase 2Small molecule
doxorubicin and cisplatin is one of 43 small molecule programs targeting Gastric Cancer. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
193 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Keytruda
Merck & Co.Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Avastin
RochePhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Cyramza
Eli LillyPhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Tuoyi
SSun Yat-sen University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for doxorubicin and cisplatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImperial College London